Other News To Note
Wednesday, September 5, 2012
Evolva Holding SA, of Reinach, Switzerland, reported further data for the first 32 patients enrolled in its Phase IIa study of EV-077, a reversible antagonist of isoprostanes and prostanoids, showing that, when given orally to Type II diabetes patients, the drug provided antiplatelet activity, reduced exercise-induced proteinuria and increased forearm blood flow.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.